The authors regret that the trade name “Acriptega” should be replaced by “Kocitaf” in this article, because the “Acriptega” represents the antiviral regimen of TDF + FTC + DTG, and the “Kocitaf” represents the TAF + FTC + DTG regimen. Although it does not affect the conclusion, it is an obvious error. The authors apologize for any inconvenience caused to the journal and readers.
Footnotes
Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.
Contributor Information
Yali Wang, Email: wangyali@csu.edu.cn.
Erik De Clercq, Email: erik.declercq@kuleuven.be.